Skip to content
Screener

Nuvation Bio NUVB Pre-Tax Income

Pre-Tax Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Pfizer logo
PfizerPFE
-$653M-121%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.66M+1.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$33.44M+22.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$91M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.79M-387%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Net gain (loss) on disposal of fixed assets1(34)1(34)
Other income (expense)5(14)4431,438
Total other (expense) income, net(11,804)4,582(10,288)10,350
Loss before income taxes(62,840)(59,007)(57,443)(112,243)
Provision for income taxes
Net loss$(62,840)$(59,007)$(57,443)$(112,243)
Net loss per share attributable to common stockholders, basic and diluted$(0.18)$(0.17)$(0.17)$(0.33)
Weighted average common shares outstanding, basic and diluted348,770340,746348,055339,685

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's pre-tax income?
Nuvation Bio (NUVB) reported pre-tax income of -$62.84M in Q2 2026.
How has Nuvation Bio's pre-tax income changed year-over-year?
Nuvation Bio's pre-tax income decreased by 6.5% year-over-year, from -$59.01M to -$62.84M.
What is the long-term trend for Nuvation Bio's pre-tax income?
Over 4 years (2021 to 2025), Nuvation Bio's pre-tax income has grown at a 23.9% compound annual growth rate (CAGR), from -$86.85M to -$204.63M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Nuvation Bio's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude